Abstract
Helicobacter pylori (H. pylori) is a gram negative, spiral, microaerophylic bacterium that infects the stomach of more than 50% of the human population worldwide. H. pylori is well recognized as a critical factor in the majority of patients with peptic ulcer disease and successful treatment results in cure of the disease. On the other hand, H. pylori infection has been associated with several extra-intestinal diseases such as hepatic encephalopathy. In this study, a triple treatment was used in management and eradication of H. pylori infection. We hypothesized that H. pylori infection and/or eradication treatment increased the releasing of α-glutathione S-transferase (α-GST). We also investigated whether α-GST is a more sensitive marker than aminotransferases (traditional liver function tests) for hepatocellular damage. However, we did not find any association between both H. pylori infection and eradication treatment and α-GST levels. According to our data, eradication treatment did not cause hepatocellular damage.
Keywords: Alkaline Phosphatase (AP), Chronic Liver Disease, Helicobacter pylori, Glutathione S-transferase immunoassay, Liver Function Tests
Current Drug Safety
Title: Release of α-Glutathione s-Transferase (α-GST) and Hepatocellular Damage Induced by Helicobacter pylori and Eradication Treatment
Volume: 2 Issue: 1
Author(s): Bensu Karahalil, Seyhan Yagar and Yasemin Ozin
Affiliation:
Keywords: Alkaline Phosphatase (AP), Chronic Liver Disease, Helicobacter pylori, Glutathione S-transferase immunoassay, Liver Function Tests
Abstract: Helicobacter pylori (H. pylori) is a gram negative, spiral, microaerophylic bacterium that infects the stomach of more than 50% of the human population worldwide. H. pylori is well recognized as a critical factor in the majority of patients with peptic ulcer disease and successful treatment results in cure of the disease. On the other hand, H. pylori infection has been associated with several extra-intestinal diseases such as hepatic encephalopathy. In this study, a triple treatment was used in management and eradication of H. pylori infection. We hypothesized that H. pylori infection and/or eradication treatment increased the releasing of α-glutathione S-transferase (α-GST). We also investigated whether α-GST is a more sensitive marker than aminotransferases (traditional liver function tests) for hepatocellular damage. However, we did not find any association between both H. pylori infection and eradication treatment and α-GST levels. According to our data, eradication treatment did not cause hepatocellular damage.
Export Options
About this article
Cite this article as:
Karahalil Bensu, Yagar Seyhan and Ozin Yasemin, Release of α-Glutathione s-Transferase (α-GST) and Hepatocellular Damage Induced by Helicobacter pylori and Eradication Treatment, Current Drug Safety 2007; 2 (1) . https://dx.doi.org/10.2174/157488607779315426
DOI https://dx.doi.org/10.2174/157488607779315426 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine Src Inhibitors and Angiogenesis
Current Pharmaceutical Design Role of MMPs in Metastatic Dissemination: Implications for Therapeutic Advances
Current Pharmaceutical Biotechnology Smac-Derived Aza-Peptide As an Aminopeptidase-Resistant XIAP BIR3 Antagonist
Protein & Peptide Letters Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
Current Pharmaceutical Design Synthesis and Cytotoxicity Studies on Novel Piperazinylacetamides
Letters in Drug Design & Discovery Clinical Signs, Prevention and Treatment of Viral Infections in Infants
Infectious Disorders - Drug Targets Beneficial Action of Citrus Flavonoids on Multiple Cancer-Related Biological Pathways
Current Cancer Drug Targets Plasma-Free Amino Acid Profiling of Nasal Polyposis Patients
Combinatorial Chemistry & High Throughput Screening Artemisinin, Promising Lead Natural Product for Various Drug Developments
Mini-Reviews in Medicinal Chemistry Short-Chain Fatty Acid Inhibitors of Histone Deacetylases: Promising Anticancer Therapeutics?
Current Cancer Drug Targets Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies
Current Gene Therapy Recent Advances in the Design and Synthesis of Small Molecule Carbonic Anhydrase IX Inhibitors
Current Topics in Medicinal Chemistry Tumor Necrosis Factor: How to Make a Killer Molecule Tumor-Specific?
Current Cancer Drug Targets Current Progress in Antifibroitcs
Current Medicinal Chemistry Multiple Forms of Proteasomes and their Role in Tumor Fate
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Antinociceptive Investigations of Niranthin in Complete Freund’s Adjuvant- induced Chronic Pain in Mice
Recent Advances in Inflammation & Allergy Drug Discovery